With a bit of a delay, here is the good news in MS-world that found its way to the media in December 2013!
- Provincial MS strategy applauded
Announced Nov. 25, Health Minister Fred Horne said the strategy – The Way Forward – “connects the dots” in the health care system so that Alberta’s almost 14,000 multiple sclerosis (MS) patients can access resources and find supports more easily.
- Teva and Takeda Announce Agreement for Glatiramer Acetate for Multiple Sclerosis Treatment in Japan
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva’s innovative glatiramer acetate (active ingredient) formulation for the treatment of multiple sclerosis, in Japan. Teva and Takeda are currently working on further agreements in connection with the implementation of this license.
- Molecular sensor detects early signs of multiple sclerosis, Gladstone study finds
In a new study from the laboratory of Gladstone Investigator Katerina Akassoglou, PhD, scientists reveal in animal models that the heightened activity of a protein called thrombin in the brain could serve as an early indicator of MS. By developing a fluorescently labeled probe specifically designed to track thrombin, the team found that active thrombin could be detected at the earliest phases of MS—and that this active thrombin correlates with disease severity. These findings, reported online in Annals of Neurology, could spur the development of a much-needed early-detection method for this devastating disease.
- Nursing Researchers Receive $2.2 Million NIH Grant for Multiple Sclerosis Cognitive Rehabilitation Study
Alexa Stuifbergen, dean of The University of Texas at Austin School of Nursing, and Heather Becker, a research scientist at the school, have received a $2.2 million National Institutes of Health (NIH) grant to continue their study on improving the quality of life for people coping with multiple sclerosis (MS), particularly those with cognitive impairments.
- New strategy to treat multiple sclerosis shows promise in mice
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
- VIDEO: UL physio’s research on benefits of physical activity for MS patients
Physiotherapist, Dr Susan Coote, has been given the funding by Ireland’s Health Research Board (HRB) to look into the chronic progressive condition of the central nervous system.
- StemGenex(r) Continues to Announce Groundbreaking Stem Cell Therapies for MS Patients
StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced the newest therapy to assist patients diagnosed with Multiple Sclerosis.
- Tuberculosis Vaccine Helps Prevent Multiple Sclerosis in Study
Researchers recruited 73 people who had a first episode suggestive of multiple sclerosis, an autoimmune disease that can be difficult to diagnose. Five years later, almost 60 percent of those given the TB vaccine hadn’t developed multiple sclerosis compared with a third of the group that received a placebo instead, according to a study today in the journal Neurology.
- “Dancing with the Stars” Finalist Jack Osbourne Offers Inside Look at His Life with Multiple Sclerosis through You Don’t Know Jack About MS(TM) Campaign
Television host and film and TV producer, Jack Osbourne, is helping to raise awareness about multiple sclerosis (MS), through a new campaign called You Don’t Know Jack About MS(TM). The online documentary series, sponsored by Teva Pharmaceuticals, chronicles Jack Osbourne and his life with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, in which a person experiences episodes of worsening neurologic functioning followed by periods of remission in which partial or complete recovery occurs.
- Aussie scientists develop quick way of testing multiple sclerosis
Scientists from the Australian Center of Excellence in Vision Science (ACEVS) based at the Australian National University (ANU) have used an instrument they are developing to accurately measure the pupil responses of MS patients and have found that the pupils of MS sufferers respond appreciably slower, the ANU said in a press release on Thursday.
- Could a vaccine help ward off multiple sclerosis?
A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis (MS) in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology
- An eye test for MS
Dr Eman Ali and her ACEVS colleagues have used an instrument they are developing to accurately measure the pupil responses of MS patients and have found that the pupils of MS sufferers respond appreciably slower. The finding opens the door to a simple and quick way of tracking the severity of MS over time: the slower the response, the worse the MS.
- Masta Ace Reveals He Has Multiple Sclerosis
After living with Multiple Sclerosis for more than a decade, Masta Ace for the first-time discusses his life with the disease.
- Gladstone researchers find ‘kick-start’ of multiple sclerosis
The protein thrombin then coverts fibrogen into fibren, a fibrous substance, formed in the coagulation of the blood, and, since fibren aren’t suppose to be in the brain; it triggers the body’s immune response.
- TB vaccine may prevent MS
“It is possible that a safe, handy and cheap approach will be available immediately following the first [episode of symptoms suggesting MS],” said study lead author Dr Giovanni Ristori, of the Centre for Experimental Neurological Therapies at Sant’Andrea Hospital in Rome.
- David Tennant and Roger Moore design cards for MS charity
Scottish actor David Tennant and Bond legend Sir Roger Moore are among the stars who have designed special cards to raise money for a multiple sclerosis charity. The gifts have been put up for sale on eBay.com along with certificates of authenticity to raise funds for the Multiple Sclerosis Society, which supports patients diagnosed with the disease.
- Reid tackles toughest challenge yet
At an age most people are looking to slow down, Denis Reid has taken on the role of Queanbeyan’s marathon man. Since taking part in his first City2Surf event in 2009, Reid has run, and run, and run, all in the name of raising awareness of, and funds to fight, Multiple Sclerosis. And this weekend the 65-year-old will tackle his most ambitious challenge yet as he hits the road in an attempt to run from the coastal city of Eden to his hometown of Bombala.
- St. Lawrence University study discovers nanoparticle that may help multiple sclerosis patients
Karin Heckman, assistant professor of biology, and William E. DeCoteau, associate professor of psychology, were lead authors on a research paper, published in a scientific journal, that examined cerium oxide nanoparticles and their ability to alleviate the symptoms of multiple sclerosis.
- Link between Epilepsy and MS
This study was conceived of and led by Alexander N. Allen of the University of Oxford, Brasenose College, Radcliffe Square, Oxford, UK. The researchers analyzed two sets of data consisting of hospital admission records from the Oxford Record Linkage Study (ORLS), collected between 1963 and 1998, along with data covering all of England from 1999 through 2011. Epilepsy and MS are fairly common conditions and would have a reasonable chance of occurring in the same person. This study was conceived to see if the two occurred more often together than expected by chance.
- UK cost agency recommends new Sanofi MS pill
Britain’s healthcare cost watchdog NICE has recommended that the state health service use Sanofi’s new multiple sclerosis pill Aubagio, which will be supplied at a discount. The National Institute for Health and Clinical Excellence (NICE) – the body that decides if drugs should be paid for – said on Friday its final draft guidance recommended Aubagio, or teriflunomide, for adults with relapsing-remitting multiple sclerosis. The drug’s list price is 13,529 pounds ($22,100) per patient a year but the size of the discount has not been disclosed.
- Woman Says Stem Cells Helping Her Fight MS
A local woman says her trip to Russia for a what’s considered an experimental treatment in this country, has given her freedom. Brooke Slick didn’t quality for U.S. trials of a stem cell transplant for multiple sclerosis, so she had it done in Moscow this spring. Now she’s working on her recovery back here at home.
- Genzyme Says Health Canada Approves Lemtrada For Multiple Sclerosis
Genzyme, a Sanofi company (SNYNF, SNY), Friday said Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis or RRMS, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.
- Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis (RMS). Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
- Study Shows That Stress Can Lead to MS Flare-Ups
Researchers at Northwestern University wanted to see if stressful events—whether positive or negative—could predict the formation of new brain lesions in those with MS. They followed 121 MS patients who agreed to undergo regular magnetic resonance imaging (MRI) scans to monitor their disease activity. Over the course of four years, half of the patients underwent stress management therapy for MS while the other half did not.
- Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award
A team led by the Accelerated Cure Project for Multiple Sclerosis (ACP) has been approved for a funding award by the Patient-Centered Outcomes Research Institute (PCORI) to create the Multiple Sclerosis Patient-Powered Research Network (MS-PPRN). The MS-PPRN is one of 29 health data networks that were approved for a total of $93.5 million from PCORI to form the PCORnet: the National Patient-Centered Clinical Research Network, a new national resource that aims to boost the efficiency of health research.
- Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the Australian Therapeutic Goods Administration (TGA) has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.
- Major Advancements Made in 2013 Toward Treating and Understanding MS Reports National MS Society
The National MS Society continues to pursue all promising paths to uncover solutions for everyone with MS, wherever those opportunities exist, with particular focus on progressive MS, nervous system repair, and wellness/lifestyle. The current year, 2013, has shown positive results from previous investments in research and the Society is committed to expanding its research funding to further speed these advances.
© WVE and Ireland, MS and Me, 2011-2013. Unauthorised use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to WVE and Ireland, MS and Me with appropriate and specific direction to the original content.